Business
Sobi Q4 and FY 2025 report: Closing the year with significant growth and strategic progress
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter and full year of 2025.
About this update from Swedish Orphan Biovitrum Ab
[{"type":"text","content":"STOCKHOLM, Feb. 5, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter and full year of 2025.","length":160,"tagName":"p"},{"type":"text","content":"Fourth Quarter 2025","length":19,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue increased 5 per cent, 16 per cent at CER1, to SEK 7,821 M (7,436)","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Haematology revenue increased 25 per cent at CER to SEK 5,143 M (4,487), mainly driven by strong sales of Altuvoct of SEK 1,023 M (302) and of Doptelet of SEK 1,508 M (1,147), somewhat offset by lower sales of Vonjo of SEK 327 M (416)","length":234,"tagName":"p"}]},{"val":[{"type":"text","content":"Immunology revenue increased 2 per cent at CER to SEK 2,337 M (2,564), driven by strong sales of Gamifant of SEK 763 M (512) and Kineret sales of SEK 741 M (777), offset by lower Beyfortus royalty of SEK 849 M (1,207)","length":217,"tagName":"p"}]},{"val":[{"type":"text","content":"Revenue from the strategic portfolio1 grew by 37 per cent at CER to SEK 5,059 M (4,099)","length":87,"tagName":"p"}]},{"val":[{"type":"text","content":"The adjusted EBITA margin1,2 was 41 per cent (34), excluding IAC2 of SEK -142 M. EBITA1 was SEK 3,075 M (2,572), corresponding to a margin of 39 per cent (35). EBIT was SEK 2,358 M (1,662)","length":188,"tagName":"p"}]},{"val":[{"type":"text","content":"Earnings per share (EPS) before dilution was SEK 5.39 (4.07) and EPS after dilution was SEK 5.34 (4.02). Adjusted EPS before dilution1 was SEK 5.70 (4.03) and adjusted EPS after dilution1 was SEK 5.65 (3.98)","length":207,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash flow from operating activities was SEK 2,981 M (1,797)","length":59,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1071,"olType":false},{"type":"text","content":"Full Year 2025","length":14,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue increased 8 per cent, 15 per cent at CER to SEK 28,238 M (26,027). Haematology grew 23 per cent at CER and Immunology grew 1 per cent at CER","length":154,"tagName":"p"}]},{"val":[{"type":"text","content":"The adjusted EBITA margin1,2 was 40 per cent (36), excluding IAC2","length":65,"tagName":"p"}]},{"val":[{"type":"text","content":"The board...